NVO

Novo Nordisk A/S
CAPPED RATING

Novo Nordisk A/S (NVO) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (A-); its weakest is Revisions (F). The rating has held at C for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B
Factor Score 3.4 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
A-
Factor Score 3.9 / 5.0
Momentum
C
Factor Score 2.5 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 10.3
EV / EBITDA 1.5
Rev Growth YoY 5.6%
Gross Margin 83.3%
Price Return 3M -10.3%
Price Return 12M -13.2%
Catalyst Signal 0.00
Market Cap $179.2B
TTM Revenue $333.7B
Price / Sales 0.5
ROE 58.4%

Historical Factor Score Progression

Held C for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B (3.4) D+ (1.8) A- (3.9) C (2.5) F (0.0) C (2.3)
2026-11-06 B (3.4) D+ (1.8) A- (3.9) C (2.4) F (0.0) C (2.3)
2026-10-30 B (3.4) D+ (1.8) A- (3.9) C (2.2) F (0.0) C (2.3)
2026-10-23 B (3.4) D+ (1.8) A- (3.9) C (2.2) F (0.0) C (2.3)
2026-10-16 B (3.4) D+ (1.8) A- (3.9) C (2.3) F (0.0) C (2.3)
Page 1 of 4